The clinical utility if PD-L1 expression is limited due to the substantial amount of tumor tissue required for its determination and the absence of a standardized quantitative scoring system for immune cells or PD-L1 immunohistochemistry (48). This evidence concerns the gene CD274 and neoplasm.